Company Description
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific.
The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.
The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
| Country | Israel |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 86 |
| CEO | Marvin Slosman |
Contact Details
Address: 4 Menorat Hamaor Street Tel Aviv, 6744832 Israel | |
| Phone | 972 3 6917691 |
| Website | inspiremd.com |
Stock Details
| Ticker Symbol | NSPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001433607 |
| CUSIP Number | 45779A853 |
| ISIN Number | US45779A8466 |
| Employer ID | 26-2123838 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Marvin L. Slosman | President, Chief Executive Officer and Director |
| Craig Shore | Chief Financial Officer, Chief Administrative Officer, Secretary and Treasurer |
| Shane Thomas Gleason | Chief Commercial Officer |
| Andrea Tommasoli | Chief Operating Officer |
| Amir Kohen | Executive Vice President of Finance and Regional Manager |
| Dr. Patrick A. Verta DVM, M.D., MS Stat | Executive Vice President of Clinical and Medical Affairs |
| Pete J. Ligotti | Executive Vice President and GM of North America |
| Dr. Sol J. Barer Ph.D. | Special Advisor to the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Dec 12, 2024 | 8-K | Current Report |
| Dec 9, 2024 | 8-K | Current Report |
| Dec 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |